TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic ...
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC ...
The Switch 2's new Accessibility menu lets you enable various features to help you use the system if you have visual, auditory, or verbal difficulties. You can tweak the size of system text, toggle a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results